Treatment of Dogs with Oral Melanoma Recurrence by Diode Laser Excision (original) (raw)
Related papers
Journal of the American Veterinary Medical Association, 2014
Scientific Reports 401 SMALL ANIMALS/ EXOTIC M alignant melanoma is the most common oral tumor in dogs and can be a devastating disease in both human and canine patients. 1-4 This type of tumor is locally invasive and highly metastatic. 1-4 Current treatment recommendations are local control with curative-intent surgery or radiation therapy (or both) and systemic adjunctive therapy. 1-4 Although local control through wide excision with or without radiation therapy has been Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001-2012
Electrochemotherapy Combined with Standard and CO2 Laser Surgeries in Canine Oral Melanoma
Slovenian Veterinary Research, 2017
Oral melanomas commonly occur in elderly dogs resulting in darkly pigmented areas of the mouth, tongue and gums. The main object of this study was a severe melanoma diagnosed in the jaw of a 15-year-old dog and its palliative treatment with electrochemotherapy. The tumour spread throughout the jaw including bones. Electrochemotherapy (ECT) with bleomycin and calcium solution (CaCl 2) was combined with standard and CO 2 laser surgeries. The treatment resulted in good local control of the tumour mass after one ECT session with bleomycin and a second ECT session with calcium ions solution. ECT significantly reduced bleeding and enhanced success of the surgery. The combination of ECT with surgical debulking resulted in rapid recovery and regaining of physiological activities, including normal feeding by the dog. This case demonstrates that the protocol combining ECT and surgery is promising in palliative melanoma treatment.
ORAL MELANOMA IN A DOG - CASE REPORT (Atena Editora)
ORAL MELANOMA IN A DOG - CASE REPORT (Atena Editora), 2023
Malignant melanoma is the most common malignant tumor of the oral cavity in dogs, it has a poor prognosis because the appearance of metastasis and/or recurrence is common, and also because it is most often diagnosed late. Survival of affected animals varies according to the treatment used, the condition of the tumor and the animal, but it does not usually exceed one year. A dog, SRD, 11 years old, not castrated, who had a nodule in the oral region, was treated. Clinical examinations, chest X-ray, blood count, biochemical tests to assess ALT and creatinine levels, and cytological examination by biopsy of the mass were performed. The exams indicated oral melanoma, with enlargement of the right mandibular lymph node and elevation in the ALT level. In a subsequent ultrasound, a hypoechoic and homogeneous liver was detected. The treatment proceeded with surgical excision of the nodule, and its referral for histological evaluation. As pre-anesthetic mediation, tiletain with zolazepam and methadone hydrochloride were used, followed by induction with propofol and maintenance with isoflurane. After surgery and anesthetic recovery, the patient was discharged with prescribed drug treatment and did not return to the hospital. The result of the histological examination showed malignant oral melanoma. The objective of this work is to compare the case report in question with a review of the literature on oral melanomas in dogs.
Comparative Aspects of Canine Melanoma
Veterinary sciences, 2016
Melanomas are malignant neoplasms originating from melanocytes. They occur in most animal species, but the dog is considered the best animal model for the disease. Melanomas in dogs are most frequently found in the buccal cavity, but the skin, eyes, and digits are other common locations for these neoplasms. The aim of this review is to report etiological, epidemiological, pathological, and molecular aspects of melanomas in dogs. Furthermore, the particular biological behaviors of these tumors in the different body locations are shown. Insights into the therapeutic approaches are described. Surgery, chemotherapy, radiotherapy, immunotherapy, and the outcomes after these treatments are presented. New therapeutic perspectives are also depicted. All efforts are geared toward better characterization and control of malignant melanomas in dogs, for the benefit of these companion animals, and also in an attempt to benefit the treatment of human melanomas.
Veterinary ophthalmology, 2016
To evaluate effectiveness and safety of debulking and diode laser photocoagulation (DPC) for the treatment of limbal melanoma (LM). Retrospective multi-institutional case series. Medical records of animals diagnosed with LM at the Centro Veterinario Specialistico (CVS) and at the Long Island Veterinary Specialists from 1994 to 2014 were retrieved. Signalment, location, extent of tumors, recurrence rate, and early and late complications were reported. Patient follow-up information was obtained from veterinary ophthalmologists, primary care veterinarians, and where appropriate, owners. Twenty-one eyes of 21 dogs (13 females and 8 males) were included in this study. The dogs' average age was 6 years (range: 7 months-11 years). The follow-up period ranged from 1-108 months (median 48 months) after the last DPC procedure. Long-term follow-up was obtained by telephone interviews in 6 of 20 cases and by clinical re-evaluations in 14 of 20 cases. The most common early complications were...
The Canadian veterinary journal = La revue veterinaire canadienne, 2018
The medical records of 87 dogs treated with surgery for cutaneous malignant melanoma (CMM) of the haired skin were retrospectively reviewed for overall survival time (OST), progression-free survival time (PFS), and prognostic factors. The post-surgery median PFS and median OST were 1282 days and 1363 days, respectively. The post-surgery metastatic rate was 21.8% with a local recurrence rate of 8%. Increasing mitotic index (MI) was predictive of a significantly decreased OST and PFS on multivariable analysis [hazard ratio (HR): 1.05, 95% confidence interval (CI): 1.02 to 1.07 and HR: 1.04, 95% CI: 1.02 to 1.06, respectively]. Increasing age was likewise predictive of a significantly decreased OST and PFS on multivariable analysis (HR: 1.39, 95% CI: 1.17 to 1.65 and HR: 1.33, 95% CI: 1.14 to 1.54, respectively). These results confirm clinical impressions that long survival times are likely in dogs diagnosed with malignant melanoma of the haired skin when treated with surgery alone.
A Retrospective Analysis of 140 Dogs with Oral Melanoma Treated with External Beam Radiation
Veterinary Radiology & Ultrasound, 2003
Despite the early notion that canine oral malignant melanoma is radioresistant, recent data suggest that external beam radiotherapy is effective in local tumor control. However, optimal fractionation schedules have not been established. The high rate of regional and distant metastasis is another problem that has hindered long-term control. The role of chemotherapy in the management of canine oral melanoma has also not been determined. In this study, data from 140 dogs irradiated at North Carolina State University were evaluated with the following objectives: (1) to compare the efficacy of three radiation therapy protocols (36 Gy, 9 Gy x 4 fractions; 30 Gy, 10 Gy x 3 fractions; or 245 Gy, 2-4 Gy x 12-19 fractions) for the treatment of dogs with oral malignant melanoma, (2) to identify any host or tumor factors influencing prognosis, and (3) to determine the impact of systemic chemotherapy on treatment outcome. Information regarding response to therapy, disease progression, and survival were determined from the medical records or from information obtained by telephone or mail survey. Relationships between host, tumor, and treatment variables and outcome measures (response, time to first event, and survival) were evaluated using Fisher's exact test (response) and the Cox regression model (time to first event and survival). The median time to first event for the 140 dogs was 5.0 months (95% C.I., 4-6 months) and the median survival was 7.0 months (95% C.I., 6-9 months). In the univariate analysis, the following variables were associated with increased time to first event and survival: (1) rostra1 tumor sublocation; (2) lack of bone lysis observed on skull imaging, and (3) microscopic tumor burden. In a multivariate analysis of 111 dogs with complete data for these variables, tumor sublocation, bone lysis, and tumor volume were identified as joint predictors of time to first event (p < .001, p < .001, and p = .04, respectively) and survival (p < .001, p < .001, and p = .05, respectively). There were no differences in response, time to first event and survival between the three radiation therapy protocols used. Systemic chemotherapy had no impact on the development of metastatic disease, time to first event, or survival, although the dosages used in this study were suboptimal. External beam radiation therapy is effective in local disease control of canine oral malignant melanoma; however, the optimal fractionation scheme has yet to he determined. The high metastatic rate observed with this disease and the inefficacy of systemic chemotherapy indicate that further investigation into novel therapies is warranted.
Treatment of Canine Oral Melanoma with Adjuvant Chemotherapy and Immunotherapy
Acta Scientiae Veterinariae, 2021
Background: Melanoma is the most frequent cancer in the canine oral cavity. It shows an aggressive behavior, characterized by rapid and invasive growth and high metastatic potential. Metastasis is seen in more than 80% of dogs at time of death. Adjuvant therapy should be recommended because of potential recurrence and metastasis. Oral melanoma has a poor prognosis even when adjuvant treatments are used. There are some treatment options, but the high death rate due to the disease is still a challenge. The aim of this study was to assess the overall survival of dogs diagnosed with oral melanoma and treated with adjuvant chemotherapy and immunotherapy. Materials, Methods & Results:A retrospective analysis was carried out in 20 dogs with oral melanocytic or amelanocytic melanomas. Cases were staged according to a modified World Health Organization clinical staging system for canine oral malignant melanoma. Tumor size (T1: < 2 cm; T2: 2 - 4 cm; T3: > 4 cm), regional metastasis (N0:...
Veterinary Pathology, 2000
Diagnostic records from 338 canine oral melanomas in 338 dogs received at the Veterinary Medical Diagnostic Laboratory (1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999) were reviewed. Of these tumors, 122 plus an additional 7 metastatic melanomas of unknown origin were selected for clinical follow-up, histologic review, and immunohistochemistry. Chow Chow, Golden Retriever, and Pekingese/Poodle mix breeds were overrepresented, whereas Boxer and German Shepherd breeds were underrepresented. There was no gender predisposition and the average age at presentation was 11.4 years. Forty-nine dogs were euthanized due to recurrence or metastasis. The average postsurgical survival time was 173 days. The gingiva and the labial mucosa were the most common sites. Most tumors were composed of either polygonal cells (27 cases, 20.9%), spindle cells (44 cases, 34.1%), or a mixture of the two (polygonal and spindle) (54 cases, 41.9%). Clear cell (3 cases, 2.3%) and adenoid/papillary (1 case, 0.8%) patterns were uncommon. The metastases of 6/6 oral melanomas had morphologic and immunohistochemical features similar to those of the primary tumors. Immunohistochemically, Melan A was detected in 113/122 oral (92.6%) and 5/7 (71.9%) metastatic melanomas. Only 4/163 nonmelanocytic tumors were focally and weakly positive for Melan A. Antibodies against vimentin, S100 protein, and neuron-specific enolase stained 129 (100%), 98 (76%), and 115 (89.1%) of 129 melanomas, respectively. Antibodies against other melanocyticassociated antigens (tyrosinase, glycoprotein 100) did not yield adequate staining. We conclude that Melan A is a specific and sensitive marker for canine melanomas.